An Update on Laboratory Diagnostics in Haemophilia A and B

Jens Müller¹  Wolfgang Miesbach²  Florian Prüller³  Thomas Siegemund⁴  Ute Scholz⁵  Ulrich J. Sachs⁶ and Standing Commission Labor (STAEKOLA) of the Society of Thrombosis and Haemostasis Research (GTH)

¹Institute for Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany
²Department of Haemostaseology and Hemophilia Center, Medical Clinic 2, Institute of Transfusion Medicine, University Hospital Frankfurt, Frankfurt, Germany
³Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
⁴Division of Hemostaseology, Department of Medicine, University Hospital Leipzig, Leipzig, Germany
⁵Center of Hemostasis, MVZ Labor Leipzig, Leipzig, Germany
⁶Department of Thrombosis and Haemostasis, Giessen University Hospital, Giessen, Germany

Address for correspondence  Jens Müller, PhD, Institute for Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Venusberg-Campus 1, 53127 Bonn, Germany (e-mail: jens.mueller@ukbonn.de).

Hamostaseologie 2022;42:248–260.

Abstract

Haemophilia A (HA) and B (HB) are X-linked hereditary bleeding disorders caused by lack of activity of coagulation factors VIII (FVIII) or IX (FIX), respectively. Besides conventional products, modern replacement therapies include FVIII or FIX concentrates with an extended half-life (EHL-FVIII/FIX). Two main strategies for measuring plasma FVIII or FIX activity are applied: the one-stage clotting assay (OSCA) and the chromogenic substrate assay (CSA), both calibrated against plasma (FVIII/FIX) standards. Due to the structural modifications of EHL-FVIII/FIX, reagent-dependent assay discrepancies have been described when measuring the activity of these molecules. Assay discrepancies have also been observed in FVIII/FIX gene therapy approaches. On the other hand, nonfactor replacement by the bispecific antibody emicizumab, a FVIIIa-mimicking molecule, artificially shortens activated partial thromboplastin time–based clotting times, making standard OSCAs inapplicable for analysis of samples from patients treated with this drug. In this review, we aim to give an overview on both, the currently applied and future therapies in HA and HB with or without inhibitors and corresponding test systems suitable for accompanying diagnostics.

Keywords
► haemophilia A/B
► factor concentrates
► extended half-life products
► emicizumab
► gene therapy

Zusammenfassung

Bei der Hämophilie A (HA) und B (HB) handelt es sich um X-chromosomal vererbte Blutungsstörungen, die durch einen Mangel an Aktivität der Gerinnungsfaktoren VIII (FVIII) bzw. IX (FIX) verursacht werden. Im Rahmen entsprechender Substitutionstherapien kommen heute auch FVIII- oder FIX-Konzentrate mit einer verlängerten

received August 4, 2021
accepted after revision October 8, 2021

DOI https://doi.org/10.1055/a-1665-6232.
ISSN 0720-9355.

© 2022. The Author(s).
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany
Haemophilia A (HA) and B (HB) are X-linked hereditary bleeding disorders caused by lack of activity of coagulation factors VIII (FVIII) or IX (FIX). To date, treatment of HA and HB is dominated by replacement therapies using plasma-derived or recombinant FVIII/FIX concentrates, including those with an extended half-life (EHL-FVIII/FIX). Especially in HA, a serious side effect of factor replacement remains the development of inhibitors. Approximately 30% of treated patients are affected, and require treatment with FVIII bypassing agents, such as recombinant activated FVII (rFVIIa) or plasma-derived activated prothrombin complex concentrate (aPCC). Besides these established bypassing drugs, recombinant porcine FVIII has become available for the treatment of HA inhibitor patients.

In addition to conventional intravenous factor replacement or bypassing schemes, emicizumab, a subcutaneously administered, bispecific monoclonal antibody that mimics the cofactor functions of activated FVIII (FVIIIa), has recently been approved for the treatment of HA patients with or without inhibitors. Furthermore, 20 years after the first attempts, gene therapy is becoming a real treatment option in both HA and HB.

For diagnosis and therapy monitoring, two main strategies for measuring plasma FVIII or FIX activity are applied in laboratories worldwide: the activated partial thromboplastin time (aPTT)-based one-stage clotting assay (OSCA) and the chromogenic substrate assay (CSA); both usually calibrated against plasma (FVIII/FIX) standard preparations. Nevertheless, owing to different underlying assay principles, gene mutation-dependent assay discrepancies have been described, requiring the application of both assay types for initial diagnosis and staging of disease severity. Regarding post-infusion monitoring, recombinant FVIII/FIX concentrates also show discrepant results, on the one hand between OSCA and CSA, and, on the other hand, between different types of OSCA. Due to deviant characteristics of expressed molecules, assay discrepancies have also been observed in FVIII/FIX gene therapy. Moreover, emicizumab excessively shortens aPTT-clotting times, making this assay or aPTT-based standard OSC assays inapplicable for the analysis of samples obtained from patients treated with this FVIIIa-mimetic drug.

The aforementioned issues illustrate that monitoring of modern HA/HB treatment options, including EHL concentrates, gene therapy and nonfactor replacement (e.g., emicizumab), require correspondingly adapted and/or qualified assays to ensure accurate and meaningful results. In the present review, we aim to give an overview on the molecules and mechanisms behind these therapies and to describe suitable test systems.
is measured by addition of a corresponding chromogenic peptide substrate. Both the OSCA and the CSA are usually calibrated by the use of plasma standards calibrated against the World Health Organization (WHO) International Standard (IS) for factor VIII (and von Willebrand factor [vWF]) in plasma (available from the 'National Institute for Biological Standards and Control' [NIBSC], code: 07/316) or the WHO IS for blood coagulation factors II, VII, IX, X in plasma (NIBSC code: 09/172) by the manufacturer.13,14

Besides the general differences between OSCA and CSA, there are also significant methodological variances within these classes of assays. Regarding OSCAs, a multitude of differently composed aPTT reagents based on different contact phase activators (including ellagic acid, polyphenols, different types of silica, and kaolin) are available from different manufacturers and are used in laboratories worldwide. Within the class of CSAs, differences between assays mainly comprise the use of either human or bovine factors and differing factor compositions and concentrations.15

**Detection of FVIII/FIX Inhibitors ([Nijmegen]-Bethesda Assay)**

The detection and quantification of antibodies that inhibit (neutralise) the activity of FVIII or FIX is usually done using the Bethesda protocol.16,17 In case of FVIII inhibitor testing, the Nijmegen-modification ([Nijmegen]-Bethesda Assay [NBA]) is regularly applied.18 The basic principle of the NBA is illustrated in – Fig. 2. In brief, (heat inactivated) patient sample and, if necessary, dilutions thereof are mixed (1 + 1) with (buffered) pooled plasma ([B]PP). After incubation, the remaining factor activities are determined. In parallel, a control reaction consisting of [B]PP and factor-deficient plasma or buffer is tested. The relative activity (RA) is calculated as shown in – Fig. 2A. By definition, an inhibitor titre of one Bethesda unit (BU) per mL inhibits the factor activity by 50%, a titre of 2 BU/mL by 75% (– Fig. 2B). To exclude any determinations based on borderline or low (poorly reproducible) factor activities, the range of valid RAs is limited from 75% (defining the detection limit of 0.42 BU/mL) down to 25%. Accordingly, samples with titres of greater than 2 BU/mL need further testing with increasing dilutions (– Fig. 2B, C).

Heat inactivation of patient plasma samples (e.g., 56 °C for 30 minutes) is considered as an important pre-analytical step to eliminate remaining factor activities and to liberate anti-FVIII antibodies bound to FVIII or cross-reacting material.19,20 In principle, the kind of assay used for the measurement of remaining factor activities (OSC- or CS-assay) is of minor importance. However, the use of CSA formats may

---

**Fig. 1** Schematic overview on the principles of FVIII/FIX one-stage clotting (OSC) and (two-stage) chromogenic substrate (CS) assays. (A) OSC assays. Due to dilution of the patient sample in FVIII- or FIX-deficient plasma (containing defined amounts of the remaining coagulation factors [grey characters]), either FVIII or FIX stemming from the patient sample (black characters) becomes the only variable that influences the activated partial thromboplastin time (aPTT) of the mixture: in brief, addition of the aPTT reagent activates the intrinsic, non-Ca²⁺-dependent pathway of the mixture (down to FXI[a]) during initial incubation. After recalci

**Fig. 2** A) Schematic overview on the principles of FVIII/FIX one-stage clotting (OSC) and (two-stage) chromogenic substrate (CS) assays. (A) OSC assays. Due to dilution of the patient sample in FVIII- or FIX-deficient plasma (containing defined amounts of the remaining coagulation factors [grey characters]), either FVIII or FIX stemming from the patient sample (black characters) becomes the only variable that influences the activated partial thromboplastin time (aPTT) of the mixture: in brief, addition of the aPTT reagent activates the intrinsic, non-Ca²⁺-dependent pathway of the mixture (down to FXI[a]) during initial incubation. After recalci

**Fig. 2** B) (Two-stage) CS assays for the determination of FVIII or FIX activity, respectively. During the first stage, plasma samples are diluted and reagents (factors) that allow for activation of plasma FVIII or FIX (bold characters), assembly of the tenase complex as well as activation of FX are added (characters with grey background). After incubation, the amount of generated FXa is quantified during the second stage of the procedure by addition of a chromogenic peptide substrate (CS). Underlying original plasma FVIII or FIX activities are again calculated from corresponding plasma calibrators.
generally lower the potential interference of non-target inhibitory substances such as lupus anticoagulants and may therefore increase assay specificity.\textsuperscript{21,22}

**Commonly Used OSC and CS Assay Reagents**

A recent survey initiated by the section ‘haemophilia’ of the German (D), Austrian (A), and Swiss (CH) Society of Thrombosis and Haemostasis Research (GTH) among haemophilia centres in the DACH countries revealed that the majority of centres primarily apply the OSCA format for both plasma FVIII and FIX activity measurements. Nevertheless, more than 80% of centres also have a FVIII CSA available, while the application of a FIX CSA is less common. Manufacturers of the used coagulation analysers are Siemens Healthineers ([Siemens], Erlangen, Germany), IL Werfen (Barcelona, Spain), and Stago (Asnières-sur-Seine, France). Accordingly, the most often applied aPTT reagents comprise the following: Actin, Actin FS, Actin FSL, and Pathromtin SL (Siemens); APTT-SP, SynthAFax, and SynthASil (IL Werfen); STA-PTT Automate (A), (STA-)Cephascreen, and (STA-)C.K. Prest (Stago). The most common FVIII CSA include the following: FVIII Chromogenic Assay (Siemens), Electrachrome FVIII (IL Werfen), TriniCHROM FVIII:C (Stago), COMATIC FACTOR VIII (Chromogenix/IL), BIOPHEN FVIII:C (Hyphen-Biomed, Neuville-sur-Oise, France), and TECHNOCHROM FVIII:C (Technoclone, Vienna, Austria). Regarding chromogenic determination of FIX activity, only two CE/IVD-marked FIX CS assays are currently available on the European market: the BIOPHEN FIX (Hyphen-Biomed) and the Rox Factor IX assays (Rossix, Mölndal, Sweden). In this article, with respect to potential specific assay discrepancies, we focus on the aforementioned reagents and kits.

**Assay Discrepancies in the Diagnosis of HA and HB**

Discrepancies between the two major test principles (OSCA and CSA) have been observed in patients with mild and

---

**Fig. 2** Principle of the (Nijmegen)-Bethesda Assay for quantitative determination of inhibitory antibodies against FVIII or FIX. (A) In an exemplary procedure, a heat-inactivated patient plasma sample with an inhibitor titre of 3 Bethesda units (BU)/mL is serially diluted in the respective factor-deficient plasma (or buffer) and the single dilutions are mixed with equal amounts (1+1) of (buffered) pooled plasma ([B]PP). As a control, the ([B]PP is mixed 1+1 with factor-deficient plasma. After incubation (e.g., 2 hours at 37 °C for FVIII inhibitor testing, no such long incubation required for FIX inhibitor testing), (residual) factor activities are measured and calculated relative (%) to that of the control reaction (relative activities [RA], panel C). (B) Inhibitor titres are usually given as BU/mL according to the definition that one BU/mL inhibits the FVIII/FIX activity by 50% (50% RA) and two BU/mL by further 50% (25% RA). The corresponding ideal interpolation function (including 0 BU/mL = 100% RA) that allows the calculation of BU/mL from determined RA values is shown in the graph (RA [y-axis, log\text{10}] versus BU/mL [x-axis]). The defined range of valid RAs is limited from 75% down to 25%, necessitating the testing of sample dilutions in case of inhibitor titres of > 2 BU/mL. (C) Measured factor activities and calculated RA values for the exemplary inhibitor-positive plasma sample (dilutions). Only the 1:4 dilution shows a RA value (60%) within the defined acceptable range of 25 to 75%. Based on the formula shown in panel B, a BU/mL titre of 0.74 is calculated, corresponding to 3 BU/mL in the original sample after correction for the initial dilution.
moderate forms of HA. Several gene mutations have been shown to be associated with discrepant results. In a recently published study on nonsevere HA, however, even discrepancies between different OSC assays have been observed, calling for a larger cohort study to systematically address such inter-reagent variations.

Also with respect to HB it has been reported that FIX CSA appear to correlate better with the clinical picture at least in some cases of nonsevere HB. The authors concluded that both assays are required for a correct diagnosis and classification.

Accordingly, the recent World Federation of Hemophilia (WFH) guidelines for the management of haemophilia recommends the use of more than one type of factor assay for the detection and classification of all forms of HA or HB.

**Drugs for and Monitoring of Factor Replacement Therapies in HA and HB**

**Conventional Plasma-Derived and Recombinant FVIII and FIX Concentrates**

The treatment of HA and HB has developed from transfusion of whole blood, plasma, and cryoprecipitate to more targeted replacement therapies under use of plasma-derived (pd) or recombinant (r) human FVIII or FIX concentrates.

When compared with CSA, lower OSCA-based FVIII activities have been observed for highly purified plasma-derived as well as recombinant full-length (rFL-) or B-domain-deleted (BDD)-FVIII concentrates. It is noteworthy that according to specifications of the European Pharmacopoeia, potency labeling of FVIII concentrates in Europe is usually based on results from CSAs against the WHO IS for factor VIII concentrate (NIBSC code: 07/350). Thus, depending on the applied FVIII concentrate, significantly lower FVIII activity levels may be observed when using OSCAs rather than CSAs for the analysis of post-infusion samples. Discrepancies, which are mainly attributable to assay-specific differences in phospholipid composition, usually do not exceed 20% for highly purified pd- or rFL-FVIII concentrates and, therefore, are considered to be clinically irrelevant.

Higher differences have been observed for certain recombinant BDD (rBDD)-FVIII concentrates which lack the FVIII B-domain. Morocctocog alfa (ReFacto® [AF]) has up to 50% lower activity when measured by OSCAs, with strong dependency on the aPTT reagent. To address this particular issue, a ReFacto AF Laboratory Standard for testing of plasma samples from patients receiving ReFacto AF has been made available.

In contrast to FVIII concentrates, potency labeling of FIX concentrates released to the European market is usually done using an OSCA in combination with the WHO IS for FIX concentrate (NIBSC code: 07/182). The IS for FIX as well as FVIII concentrate are plasma-derived preparations. It was demonstrated that rFIX concentrates yielded up to 30% lower activity levels in an OSCA calibrated against the IS for FIX concentrate when compared with a correspondingly calibrated CSA. Furthermore, also reagent-related discrepancies between applied OSCAs were found, while such effects were not observed when testing pd-FIX concentrates.

The aforementioned findings demonstrate that, due to structural and/or matrix-dependent differences between plasma-based assay calibrators and FVIII or FIX drug molecules, the introduction of recombinant factor concentrates led to assay discrepancies of varying degrees during both potency labeling and analyses of post-infusion samples. With the advent of modified recombinant EHL-FVIII/FIX concentrates, such discrepancies, as described below, have become more frequent.

**Extended Half-Life (EHL) FVIII and FIX Concentrates**

At present, a total of five EHL-FVIII concentrates (Damoctocog alfa pegol [Jivi®], Efmmorocctocog alfa [Elocta®], Lonoctocog alfa [Afstyla®], Rurioctocog alfa pegol [Adynovis®], and Turoctocog alfa pegol [Esperoct®]) and three EHL-FIX concentrates (Albutreponacong alfa [Idelvion®], Efmmoronacog alfa [Alprolix®], and Nonacog Beta Pegol [Refixia®]) are available in Europe. Compared with conventional plasma-derived or recombinant factor concentrates, these EHL products have a 1.2- to 1.5-fold (FVIII, corresponding to the half-life of vWF) or 5-fold (FIX) prolonged half-life in the circulation. The modifications, introduced to achieve these characteristics (fusion with Fc fragment, alumin fusion or PEGylation) have various effects on the activation and/or activity pattern of these FVIII/FIX drug molecules. Consequently, divergent assessments of factor activity compared with plasma-derived FVIII or FIX used for assay calibration are observed.

Potential assay discrepancies between commonly used test systems are described below for each factor concentrate. A synopsis is presented in Table 1.

**Efmmorocctocog Alfa (Elocta)**

Efmmorocctocog alfa (rFVIIIFc, Elocta) is a fusion protein combining a B-domain-deleted molecule and the Fc fragment of human immunoglobulin G1 (IgG1), to extend the circulatory half-life.

In an initial international field study based on FVIII deficiency plasma spiked with rFVIIIFc at different target concentrations, results obtained with various OSCAs showed good recovery and were comparable to those of correspondingly prepared rFL-FVIII preparations (Advate) analysed in parallel. During a more recent UK National External Quality Assessment Scheme for Blood Coagulation (NEQAS BC), based on spiked as well as post-infusion samples, the initial findings could be confirmed, again for a broad spectrum of applied OSCAs/aPTT reagents.

In contrast to the OSCA results, higher results for rFVIIIFc are obtained when samples are analysed by CSAs. It was assumed that these discrepancies stem from differences between the WHO IS for FVIII concentrate or plasma. However, it is generally concluded that both the OSCA and the CSA may be used to safely monitor rFVIIIFc-based factor FVIII replacement therapies. However, overestimation of Elocta by CSAs should be considered.

**Damoctocog Alfa Pegol (Jivi)**

Damoctocog alfa pegol (Jivi) is a rBDD FVIII molecule with extended half-life due to site-specific PEGylation.
### Table 1 Summary of EHL/modified FVIII/FIX concentrates and applicable test systems

| OSC assays (aPTT reagents) | EHL-FVIII concentrates | Porcine rFVIII | EHL-FIX concentrates |
|---------------------------|------------------------|---------------|---------------------|
|                           | Adynovi | Afstyla | Elocta | Esperoct | Jivi | Obizur | Alprolix | Idelvion | Refixia |
| **Activator: ellagic acid/polyphenols** | | | | | | | | | |
| Actin (Siemens) | ? | '2 | ? | ✓ | ✓ | ? | ? | ✓ | x ↓ |
| Actin FS (Siemens) | ✓✓ | ✓ | ✓ | ? | ? | ? | ? | ✓ | x ↓ |
| Actin FSL (Siemens) | ✓✓ | ✓ | ✓ | ✓ | o ↑ | ✓ | o ↑ | x ↓ | x ↓ |
| SynthAfax (IL Werfen) | ? | '2 | ? | ? | ✓ | ? | x↑ | x↑ | ✓ |
| Cephascreen (Stago) | ✓✓ | ✓ | ? | ✓ | ✓ | ✓ | o ↑ | ? | ✓ |
| **Activator: Silica** | | | | | | | | | |
| Pathromtin SL (Siemens) | ? | '2 | ✓ | ✓ | ✓ | o ↑ | ? | ✓ | ✓ | x↑ |
| APTT SP (IL Werfen) | ✓ | '2 | ? | x ↓ | x ↓ | ✓ | ? | ✓ | x↑ |
| SynthASil (IL Werfen) | ✓✓ | ✓ | ? | o ↑ | ✓ | ? | ✓ | ✓ | x↑ |
| STA PPT A (Stago) | ✓✓ | ✓ | ? | o ↑ | ✓ | ✓ | ? | x↑ | |
| **Activator: Kaolin** | | | | | | | | | |
| C.K. Prest (Stago) | ✓✓ | ✓ | ? | ✓ | ✓ | ✓ | x↓ | x↓ | x↓ |
| **FVIII CS assays** | | | | | | | | | |
| Factor VIII chromogen (Siemens) | ✓✓ | ✓ | ✓ | ✓ | o ↓ | x ↓ | x↓ |
| COAMATIC FVIII (Chromogenix/IL Werfen) | ✓ | ✓ | ✓ | ✓ | o ↓ | x ↓ | | | |
| Biophen FVIII (Hyphen-BioMed) | ? | ✓ | ✓ | ✓ | ✓ | x ↓ | x↓ | | | |
| Electrachrome FVIII (IL Werfen) | ✓✓ | ? | ✓ | ✓ | ✓ | x ↓ | x↓ | | | |
| Technochrom Factor VIII:C (Technoclone) | ? | ✓ | ✓ | ✓ | ✓ | x ↓ | x↓ | | | |
| **FIX CS assays** | | | | | | | | | |
| BIOPHEN Factor IX (Hyphen) | | | | | | | | | |
| ROX Factor IX (Rossix) | ✓ | x ↓ | ✓ | | | | | | |

Abbreviations: aPTT, activated partial thromboplastin time; EHL, extended half-life.
✓ Acceptable recoveries described in the literature, may be applied for analysis of post-infusion samples.
✓✓ Acceptable recoveries found in field study but contradictory information available.
o Moderate and/or system-dependent discrepancies described.
x Not recommended for analysis of post-infusion samples due to described significant discrepancies.
? No individual or only insufficient data available.
'2 manufacturers' recommendation to apply a conversion factor of 2 (see text for potential restrictions).
↓ Overestimation observed.
↑ Underestimation observed.
During an international field study, a variety of FVIII OSCAs and CSAs were investigated using FVIII-deficient plasma spiked with various Jivi target concentrations. Overall, good recovery and agreement of results was stated for the applied CSAs (Siemens FVIII Chromogenic Assay, Electrachrome FVIII, and COAMATIC FACTOR VIII) within this study design.\(^{46}\) While this was also true for most of the investigated OSCAs, exceptions were identified. For example, moderate overestimation especially at low-to-medium Jivi input concentrations was observed when the aPTT reagents (Actin FS, Pathromtin SL, SynthAsil or CK Prest) were used, although results were not consistent between participating laboratories.\(^{46}\) In contrast, two silica-based aPTT reagents, APTT-SP and STA-PTT A, consistently showed pronounced underestimation of Jivi, an effect that had already been observed before.\(^{47}\)

However, the earlier-described performance of OSCAs and CSAs could only be partially confirmed during more recent studies based on spiked plasma samples.\(^{48,49}\) While OSCAs based on the aPTT reagents (Pathromtin SL, SynthAsil, and CK Prest) showed more acceptable results, evaluation of different CSAs yielded more inconsistent findings. For example, when using the TriniCHROM FVIII:C assay, Jivi was underestimated by approximately 40% at all tested input concentrations.\(^{48}\) Underestimation was also observed with the Siemens FVIII Chromogenic Assay.\(^{48,49}\) In contrast, the COAMATIC FACTOR VIII and BIOPHEN FVIII:C (Hyphen-Biomed) CSA showed acceptable results.\(^{48}\)

Based on these findings, it is concluded that APTT-SP and STA-PTT A should not be used for OSC-based FVIII activity measurements in samples from patients treated with Jivi. The same is true for the TriniCHROM FVIII:C CSA. Furthermore, it appears recommendable that local laboratories evaluate the use of Actin FS, Pathromtin SL-, SynthAsil-, or CK Prest-based OSCAs as well as the Siemens FVIII Chromogenic Assay with respect to the accuracy of Jivi activity measurements.

**Lonocotocog Alfa (Afstyla)**

Lonocotocog alfa (rFVIII-SC, Afstyla) is a B-domain-truncated single-chain FVIII molecule with improved binding to vWF, resulting in a higher stability and a prolonged half-life (approximately 1.2-fold) of the molecule in the circulation.\(^{50,51}\)

Initially, an international field study based on FVIII-deficient plasma spiked with rFVIII-SC at four different input concentrations was conducted. Overall, while the applied CSAs showed good recovery and agreement of results, analysis of samples by OSCAs revealed underestimation of the activity of rFVIII-SC by approximately 45%; the finding was independent of the aPTT reagent used.\(^{52}\) Although it was shown that the interlaboratory variability of results was increased at low target concentrations, approval of Afstyla came with the stipulation that the results of activity measurements obtained with OSCAs shall be multiplied by 2 (\(>\)Table 1).\(^{57}\)

However, during a further study also based on spiked plasma samples, it was shown that, especially at low concentrations and depending on the aPTT reagent used, overestimation of Afstyla may occur when using the conversion factor as described earlier. In this regard, the aPTT reagents SynthAfax and Actin FS were particularly conspicuous.\(^{53}\)

Based on these findings, we conclude that the application of a CSA is the first choice for reliable determination of Afstyla activity in post-infusion samples. When using an OSCA in conjunction with the proposed conversion factor of 2, possible overestimation, especially at low Afstyla plasma levels, must be taken into account. While local evaluation of applied OSCAs is generally advisable, verification of SynthAfax- or Actin FS-based OSC assays is especially recommended.

**Ruriotocog Alfa Pegol (Adynovi)**

Ruriotocog alfa pegol (PEG-rFVIII, BAX 855, Adynovi) is a rFL-FVIII molecule conjugated with a polyethylene glycol (PEG) reagent (approximately 60% attached to the B-domain) for half-life extension.\(^{54}\)

In an initial international field study based on congenital FVIII-deficient plasma spiked with PEG-rFVIII at different input concentrations, obtained results showed concentration-dependent overestimation of PEG-rFVIII. However, comparable results were obtained with analogous rFL-FVIII preparations (Octocog alfa [Advate®]) tested in parallel. Especially for OSCAs that utilise aPTT reagents based on ellagic acid or polyphenol, overestimation (25–40%) was observed at lower PEG-rFVIII or Advate input concentrations. When silica- or kaolin-based aPTT reagents were used, target activity values were found. In contrast, overestimation (25–30%) of both FVIII preparations by CSAs was observed at higher PEG-rFVIII input concentrations. Overall, however, there appeared to be good comparability of measurement results between PEG-rFVIII and the conventional FVIII product Advate using a wide range of measurement systems.\(^{55}\)

In contrast to the results described earlier, another field study showed a more significant (concentration-dependent) overestimation of Adynovi when using both OSCAs and CSAs. Interestingly, this effect was also seen using product-specific calibrators.\(^{56}\) It is noted by the authors that, unlike the initial study described earlier, no congenital FVIII-deficient plasma was used for sample preparations. Furthermore, also a narrower reperatory of reagents was compared within that study.\(^{56}\)

Nevertheless, since the currently available literature contains inconsistent information regarding the reliability of test systems for the determination of Adynovi plasma activity, individual evaluation of local assays may be considered (\(>\)Table 1).\(^{57}\)

**Turoctocog Alfa Pegol (Esperoct)**

Turoctocog alfa pegol (N8-GP, Esperoct) is a rFVIII molecule with extended half-life due to site-specific (glyco)PEGylation within the truncated B-domain of the construct.\(^{58}\)

Previously performed studies revealed overestimation of Esperoct by CSA, albeit on a clinically acceptable level (<30%).\(^{59,60}\) Also during a more recent study, measuring of patients’ samples taken during the pathfinder clinical trials program showed comparable results between an applied CSA (Chromogenix Coatest SP FVIII) and an OSCA based on Actin FS.\(^{61}\)
Regarding analysis by different OSCAs, inconsistent results have been described, especially for the aPTT reagents SynthASil and SynthAFax (IL Werfen). Significant underestimation was found when APTT-SP (IL Werfen), TriniCLOT (Stago), or STA PTT-Automate (Stago) was used. According to the authors, these aPTT reagents should not be used for the analysis of Esperoct by OSCAs (Table 1). As being true for Eclocta, overestimation of Esperoct by CSAs should be considered (Table 1).

**Albutrepenonacog Alfa (Idelvion)**

Albutrepenonacog Alfa (rIX-FP, Idelvion) is a recombinant fusion protein combining a FIX molecule with albumin for extended half-life.53

In several studies, Pathromtin SL, which is also used for potency labeling of Idelvion, has been shown to be well suited as aPTT reagent in FIX OSCAs for monitoring of post-infusion samples.60,62 Although inconsistent results have been observed, most of the other applied aPTT reagents showed acceptable results, with the exception of Actin FS and CK Prest, that showed significant underestimation of Idelvion, while, in contrast, significant overestimation was found for SynthAFax as well as for the available FIX CSAs.56–68 Interestingly, it has been recently proposed that the latter is due to impaired activation of rIX-FP during Pathromtin SL (and colloidal silica)-based OSC measurements.69

On the basis of the data published to date, an OSCA for the measurement of Idelvion appears to be preferable; however, the above-described aPTT reagents should not be applied (Table 1).

**Eftrenonacog Alfa (Alprolix)**

Eftrenonacog alfa (Alprolix) is a recombinant fusion protein with extended half-life that combines a FIX molecule with the Fc fragment of human IgG1.70

While potency labeling of Alprolix is done using an OSCA based on Actin, overestimation of Alprolix especially at lower concentrations was found when using OSCAs that apply ellagic acid–based aPTT reagents. While this was especially and reproducibly true for SynthAFax, a high interlaboratory variability of results was found for other aPTT reagents tested.71,72 In contrast to the ellagic acid–based aPTT reagents, silica-based reagents showed more acceptable results, while the kaolin-based CK Prest demonstrated significant underestimation. When using a CSA for sample analysis, acceptable recoveries were found.72 However, a recent single-centre study revealed analyser-dependent differences of assay results, as well as underestimation of Alprolix by CSAs at lower input concentrations.73 Furthermore, another field study also demonstrated interlaboratory differences during analysis of Alprolix, which, however, were not different from that of pFIX and rFIX processed in parallel.74

In summary, one may conclude that, due to over- or underestimation of Alprolix, by SynthAFax or CK Prest, respectively, these two aPTT reagents should not be used in OSCAs applied for the determination of Alprolix activity.

Furthermore, local evaluation of (other) ellagic acid–based aPTT reagents should be performed (Table 1).

**Nonacog Beta Pegol (Refixia)**

Nonacog Beta Pegol (Refixia) is a recombinant FIX molecule with site-specific (glyco)PEGylation for half-life extension.75

Laboratory studies showed that the application of FIX CSAs yields acceptable results when measuring Refixia in post-infusion samples.76 In contrast, a high variability of results was found when applying a series of different OSCAs. When using polyphenol- or ellagic acid–based aPTT reagents, acceptable results (STA-Cephascreen, SynthAFax, or DG Synth), but also significant underestimation of Refixia (e.g., using Actin FS and Actin FSL), were found. Underestimation was also found when using kaolin-based CK Prest. Regarding the silica-based aPTT reagents, however, SynthASil (colloidal silica) led to an underestimation of more than 50%, while, as also true for most of the other silica-based reagents, Pathromtin SL (silicon dioxide particles) led to severe overestimation of Refixia.77 As a cause for the latter effect, it could be demonstrated that the presence of silica leads to an activation of Refixia by FXIa but also kallikrein already during the incubation phase of the aPTT reagent in the absence of Ca²⁺ ions.78

Thus, as outlined above, and also summarised in Table 1, CSAs and only selected OSCAs (aPTT reagents) appear to be suitable for reliable determination of Refixia activity in post-infusion samples.79,80

**Laboratory Diagnostics during Treatment of HA with Emicizumab (Hemlibra)**

Emicizumab (Hemlibra®) is a subcutaneously administered, humanised, monoclonal, bi-specific IgG4 antibody that binds FIX(a) and FX(a), thereby mimicking the cofactor function of FVIIIa.81 In contrast to FVIIIa, emicizumab circulates at high (target) concentrations (30–80 µg/mL [200–530 nM] as measured in plasma) and binds only with moderate affinity (KD = 1–2 μM) and non-discriminatory to the human (pro)enzyme variants of FIX(a) or FX(a). Simultaneous binding of emicizumab to FIXa and FX, both presenting properly (pro)enzyme variants of FIX(a) or FX(a), mimicking the cofactor function of FVIIIa and FIX(a) (Heizer et al., 2015) and is not subject to regulation. The former characteristic leads to significant shortening of aPTT-based clotting times even at subtherapeutic plasma concentrations of emicizumab. The reason is that emicizumab requires no thrombin-meditated feedback activation but is ‘active’ as it is. Accordingly, in the presence of emicizumab, aPTT-based OSCAs configured and calibrated for quantitative detection of plasmatic coagulation factor activity exhibit clotting times outside the dynamic range of these test systems.82,83

**Interference of Emicizumab with Established Test Systems**

In contrast to FVIII, emicizumab does not require activation and is not subject to regulation. The former characteristic leads to significant shortening of aPTT-based clotting times even at subtherapeutic plasma concentrations of emicizumab. The reason is that emicizumab requires no thrombin-mediated feedback activation but is ‘active’ as it is. According to the authors, aPTT-based OSCAs configured and calibrated for quantitative detection of plasmatic coagulation factor activity exhibit clotting times outside the dynamic range of these test systems.84,85
In contrast, emicizumab at therapeutic concentrations is dynamically detected by FVIII CSAs based on human FIXa and FX (cf. Fig. 1B). However, it is important to note that any determined ‘FVIII activities’ must not be translated to FVIII-equivalent effects of emicizumab in vivo, but are merely derived from assay calibration against FVIII. A different picture emerges when using FVIII CSAs based on bovine factors. Such assays are not able to detect emicizumab, as it only binds to human FIX(a) and FX(a), and are therefore specific tools to measure (endogenous or exogenous) FVIII in the presence of emicizumab.\(^\text{12,84,85}\) However, assays to monitor the combined effect of FVIII and emicizumab are currently not available.

**Determination of Plasma Levels of Emicizumab**

To enable the determination of emicizumab in plasma, a modified FVIII OSCA has been developed. Using a higher pre-diluted plasma sample and appropriate calibrators and controls, it determines plasma concentrations (activity) of emicizumab between 10 and 100 μg/mL, adequately covering the therapeutic range of the drug.\(^\text{6,7}\)

Using emicizumab calibrators, quantitative determination of emicizumab also appears possible using human factor-based FVIII CSAs.\(^\text{86}\) It must be noted that any additionally present FVIII may distort measurement results especially of this assay type. Should it be necessary to determine the plasma level of emicizumab in the presence of FVIII, heat inactivation of the plasma sample may be considered.\(^\text{85}\)

**Laboratory Diagnostics in HA or HB with Inhibitors**

Neutralising anti-FVIII (drug) antibodies, so-called inhibitors, occur in up to 30% of treated patients with severe HA. In contrast, the formation of FIX inhibitors in severe HB is much less common.\(^\text{4,87}\)

In case of HA or HB with inhibitors, bypassing agents such as recombinant activated FVII (rFVIIa) or aPCCs may be applied.\(^\text{88}\) In HA with inhibitors, emicizumab has become a treatment option.\(^\text{5,89}\) In addition, recombinant porcine FVIII (rpFVIII, Susoctocog alfa [Obizur®]) has been approved for the treatment of bleeding episodes in adults with acquired HA (AHA).\(^\text{5}\)

To eliminate inhibitors formed in treated HA or HB patients, immune tolerance induction (ITI) therapy is currently the therapy of choice. Hereby, FVIII or FIX concentrates are administered at high frequencies and doses. While up to 70% of HA patients with inhibitors are in remission after ITI therapy, this strategy is less successful in patients suffering from HB with inhibitors.\(^\text{87,88,90}\)

Functional detection and quantification of FVIII or FIX inhibitors is usually done using the (Nijmegen)-Bethesda assay (–Fig. 2). Furthermore, enzyme-linked immunosorbent assay (ELISA)-based analysis may be used to assess total (neutralising and non-neutralising) anti-drug antibody (ADA) levels.\(^\text{91}\) With the introduction of modified (EHL-) FVIII/FIX concentrates and emicizumab to the clinic, however, traditional testing schemes need to be adapted and/or extended.\(^\text{11}\)

**Inhibitor Testing in HA Patients Treated with Emicizumab**

As outlined earlier, emicizumab is immediately active and does not require thrombin-mediated feedback activation. In contrast to FVIII present in a sample after substitution, emicizumab cannot be inactivated by heat.\(^\text{11}\) A straightforward solution to this problem comes with the fact that emicizumab is not recognised by FVIII CSAs based on bovine factors. Accordingly, the application of such an assay for the determination of (residual) FVIII activities during NBA leads to reliable results, independent of the presence of emicizumab in the sample to be analysed.\(^\text{92}\)

**Inhibitor Testing in HA and HB Patients Treated with EHL-FVIII/FIX Concentrates**

The formation of anti-PEG has been observed in previously conventionally treated HA patients substituted with pegylated EHL-FVIII concentrates.\(^\text{93–96}\) While in the majority of cases, these antibodies did not affect FVIII function, also loss of treatment efficacy was observed.\(^\text{96}\) In these cases, the antibodies were directed against the PEG moiety, specific for the EHL-FVIII molecule and did not cross-react with unmodified FVIII. These circumstances allowed for successful further treatment of patients with conventional FVIII concentrates after observed loss of efficacy of therapy with pegylated EHL-FVIII.\(^\text{96}\)

In general, to specifically detect and quantify any inhibitory ADAs, EHL-specific (N)BA may be performed. The EHL factor to be addressed is diluted to (approx.) 1 IU/mL in (imidazole-buffered) FVIII- or FIX-deficient plasma to serve as the substrate during the assay. While this may be done using (remainders of) the reconstituted drug, the availability of corresponding laboratory standards would be favorable.

The risk of FVIII or FIX inhibitor development in previously untreated patients (PUPs) under therapy with EHL factor concentrates might be reduced but remains significant.\(^\text{97,98}\) Consequently, with respect to functional inhibitor testing by the (N)BA, this raises the question whether or not established standard conditions for heat inactivation of patient samples to eliminate any remaining factor activities (–Fig. 2) also apply for EHL-FVIII or FIX molecules. Indeed, corresponding analysis confirmed that the activity of all currently approved EHL factor concentrates can be efficiently inactivated when incubated at 56 °C for 30 minutes.\(^\text{99,100}\)

**Monitoring of and Inhibitor Testing in the Treatment of AHA with Susoctocog Alfa (Obizur)**

Susoctocog alfa (Obizur) is a rpFVIII concentrate approved for the treatment of acute bleedings in AHA. In contrast to human (EHL-)FVIII concentrates, however, potency labeling of Obizur uses a FVIII OSCA rather than a CSA.\(^\text{35}\) In an international field study, based on congenital FVIII-deficient plasma spiked with Obizur at different input concentrations, OSCAs with a variety of aPTT reagents showed acceptable results. In contrast, applied CSAs underestimated the activity
of Obizur by approximately 50%. Accordingly, a FVIII OSCA should be used for both, monitoring of Obizur plasma levels during therapy as well as determination of (residual) FVIII activities in Obizur-specific NBAs (= Table 1).

Indeed, while Obizur has been developed with the intention to bypass neutralising antibodies against human FVIII, cross-reactivity of such inhibitors with the underlying rpFVIII molecule has been described.107 Thus, it may become necessary to perform specific testing for inhibitors against Obizur. For doing so, a corresponding laboratory standard is available from the manufacturer (Takeda). When diluted to 1 U/mL in (imidazole-buffered) FVIII-deficient plasma, this mixture, instead of FVIII in buffered pooled plasma (= Fig. 2A), serves as substrate during the NBA.

Outlook to Future Treatment Options

In addition to currently available treatment options for HA and HB, a variety of novel molecules and innovative therapy strategies is currently investigated in a series of clinical trials. Among others, these comprise FVIII/FIX gene therapy, factor concentrates with further improved properties and/or the possibility for subcutaneous administration as well as strategies for rebalancing pro- and anticoagulant mechanisms.102–105 As also true for the currently established therapies, also these novel treatment regimens do and will prompt questions about the general need for treatment monitoring but also about their impact on assay results as well as the applicability of established test systems for patient sample analysis.11,106

Currently, five (three HA and two HB) gene therapy approaches are within phase 3 clinical trials, making a licensed product possible within the near future.8

In gene constructs used for HA, the factor VIII cassette is B-domain deleted, consistently resulting in OSCA results which were approximately 1.5 times higher than those obtained with chromogenic assays.107 Interestingly, this contrasts with the factor level discrepancies found in patients treated with BDD FVIII concentrates, where OSCAs generally yields lower results than CSAs.36,65

In gene therapy for HB, a full-size FIX gene with higher specific activity than the native FIX gene (Padua variant) is most often used. FIX OSCAs yield approximately 1.5 times higher results than chromogenic assays, while aPTT-reagent-dependent differences have been observed.108

Further research is needed to determine the relative accuracy of the different assay principles in patients with gene therapy in relation to clinical response and also in relation to the results of patients treated with different factor concentrates. Recently, it has been recommended to apply both assay principles to quantify FVIII and FIX activity in gene therapy trials and that the possibly more accurate lower values measured by the chromogenic test be relied upon.10

Summary and Conclusion

High inter-laboratory variation in the measurement specifically of EHL-factors in post-infusion samples has become apparent. To some extent, this variation is considered to be within the range of ‘traditional’ (but previously less robustly examined) laboratory result variation, as observed for the measurement of conventional recombinant factor molecules. However, it was our aim to highlight that there are inappropriate test systems for certain factors, or inappropriate factors for certain test systems. Such combinations must be avoided to maintain patient safety. The treating physician and the laboratory need to harmonise their toolboxes to ensure that factor activities are assessed within acceptable ranges for all factor concentrates prescribed in the respective centre. As a minimum requirement, significant overestimation of factor activity must be excluded to ensure appropriate laboratory-based controls for prophylactic and therapeutic factor administration. While product-specific calibrators may be helpful to correct for potential assay discrepancies, this approach appears to be impractical in clinical routine due to the variety of available concentrates. However, OSCAs will still meet most requirements. Emicizumab poses considerable additional challenges, especially for small- and medium-size coagulation laboratories, because the use of CSAs becomes mandatory when examining samples from HA patients treated with this antibody. In the end, coagulation laboratories processing samples for HA and HB patients under factor replacement or alternative therapy will have to establish two different assays for FVIII and FIX, respectively: one OSCA and one CSA—at least. With new therapeutic options lying ahead, this will become more pressing during the next years.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

1 Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361(9371):1801–1809
2 Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus 2019; 17(06):479–486
3 Chowdary P. Extended half-life recombinant products in haemophilia clinical practice - expectations, opportunities and challenges. Thromb Res 2020; 196:609–617
4 Cormier M, Batty P, Tarrant J, Lillicrap D. Advances in knowledge of inhibitor formation in severe haemophilia A. Br J Haematol 2020; 189(01):39–53
5 Burness CB, Scott LJ. Susoctocog alfa: a review in acquired haemophilia A. Drugs 2016; 76(07):815–821
6 Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377(09):809–818
7 Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379(09):811–822
8 Batty P, Lillicrap D. Hemophilia gene therapy: approaching the first licensed product. HemaSphere 2021; 5(03):e540
9 Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost 2016; 14(02):248–261
10 Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020; 26(Suppl 6):1–158
Laboratory Diagnostics in Haemophilia

Müller et al.

11 Peyvandi F, Kenet G, Pekrul I, Pruthi RK, Range P, Sspanagl M. Laboratory testing in hemophilia: impact of factor and non-factor replacement therapy on coagulation assays. J Thromb Haemost 2020;18(06):1242–1255

12 Bowyer AE, Lowe AE, Tiefenbacher S. Laboratory issues in gene therapy and emicizumab. Haemophilia 2021;27(Suppl 3):142–147

13 Hubbard AR, Hamili M, Beeharry M, Bevan SA, Heath ABSSC Sub-Committees on Factor VIII/Factor IX and von Willebrand factor of ISTH. Value assignment of the WHO 6th International Standard for blood coagulation factor VIII and von Willebrand factor in plasma (07/316). J Thromb Haemost 2011;9(10):2100–2102

14 Wilmot HV, Rakowski K, Gray E. The traceability of commercial plasma calibrators to the plasma international standards for factor VIII and factor IX. Int J Lab Hematol 2020;42(06):810–818

15 Marlar RA, Strandberg K, Shima M, Adcock DM. Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B. Eur J Haematol 2020;104(01):3–14

16 Kasper CK, Aledort L, Aronson D, et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975;34(02):612

17 Gadarowski JJ Jr, Czapek EE, Ontiveros JD, Pedraza JL. Modification of the Bethesda assay for factor VIII or IX inhibitors to improve efficiency. Acta Haematol 1988;88(03):134–138

18 Verbruggen B, Novakova I, Wessels H, Boezeinan J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995;73(02):247–251

19 Boylan B, Miller CH. Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels. Haemophilia 2018;24(03):487–491

20 Miller CH, Boylan B, Shapiro AD, Lentz SR, Wicklund BM. Hemophilia Inhibitor Research Study Investigators. Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors. J Thromb Haemost 2017;15(10):1971–1976

21 Miller CH, Rice AS, Boylan B, et al; Hemophilia Inhibitor Research Study Investigators. Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening. Am J Hematol 2015;90(10):871–876

22 Rampersad AD, Boylan B, Miller CH, Shapiro A. Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophiliacs and non-haemophiliac patients. Haemophilia 2018;24(05):807–814

23 Oldenburg J, Pavlova A. Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. Hamostaseologie 2010;30(04):207–211

24 Duncan EM, Rodgers SE, McAre SJ. Diagnostic testing for mild hemophilia a in patients with discrepant one-stage, two-stage, and chromogenic factor VIII:C assays. Semin Thromb Hemost 2013;39(03):272–282

25 Bowyer AE, Van Veen JJ, Goodeve AC, Kitchen S, Makris M. Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A. Haematologica 2013;98(12):1980–1987

26 Trossaert M, Lienhart A, Nougier C, et al. Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements. Haemophilia 2014;20(04):550–558

27 Bowyer AE, Goodeve A, Liesner R, Mumford AD, Kitchen S, Makris M. p.Tyr365Cys change in factor VIII: haemophilia A, but not as we know it. Br J Haematol 2011;154(05):618–625

28 Lyall H, Hill M, Westby J, Grimley C, Dolan G. Tyr346→ Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype - is this mild haemophilia A? Haemophilia 2008;14(01):78–80

29 Sträffors A, Mikovic D, Schmidt D, et al. Genetics and hemostatic potential in persons with mild to moderate hemophilia A with a discrepancy between one-stage and chromogenic FVIII assays. Thromb Haemost 2021;121(01):27–35

30 Suzuki A, Suzuki N, Kanematsu T, et al. Impact of variation in reagent combinations for one-stage clotting assay on assay discrepancy in nonsevere haemophilia A. Int J Lab Hematol 2021;43(01):131–138

31 Kihlborg K, Strandberg K, Rosén S, Ljung R, Astarmark J. Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B. Haemophilia 2017;23(04):620–627

32 Franchini M, Mannucci PM. The history of hemophilia. Semin Thromb Hemost 2014;40(05):571–576

33 Dodd J, Hubbard AR, Wicks SJ, et al. Potency determination of factor VIII and factor IX for new product labelling and post-infusion testing: challenges for caregivers and regulators. Haemophilia 2015;21(04):543–549

34 Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998;4(04):646–650

35 Augustsson C, Norström E, Andersson NG, Zetterberg E, Astarmark J, Strandberg K. Monitoring standard and extended half-life products in hemophilia: assay discrepancies for factor VIII and IX in pre- and post-infusion samples. Res Pract Thromb Haemost 2020;4(07):1114–1120

36 Mikaelsson M, Oswaldsson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Hematol 2001;38(02):Suppl 4:13–23

37 Poupard C, Ternisien C, Desconclois C, Nasn D, Aillaud MF, Caron C. Discrepancies between one stage assay and chromogenic substrate assay in patients treated with recombinant or plasma-derived FVIII and usefulness of a specific enzyme characterization for ReFacto A® -treated patients. Haemophilia 2016;22(02):e101–e103

38 Gray E, Pickering W, Hockley J, et al. Collaborative study for the establishment of replacement batches for human coagulation factor IX concentrate reference standards. Pharmeurop Bio 2008;2008(01):19–30

39 Wilmot HV, Hogwood J, Gray E. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays. Haemophilia 2014;20(06):891–897

40 Wilmot HV, Gray E. Potency estimates for recombinant factor IX in the one-stage clotting assay are influenced by more than just the choice of activated partial thromboplastin time reagent. Haemophilia 2018;24(05):e363–e368

41 Peters RT, Toby G, Lu Q, et al. Biochemical and functional characterization of a recombinant monomeric factor VIII:C fusion protein. J Thromb Haemost 2013;11(01):132–141

42 Sommer JM, Moore N, McCuffie-Valentine B, et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia 2014;20(02):294–300

43 Kitchen S, Jennings I, Makris M, Kitchen DP, Woods TAL, Walker ID. Cloting and chromogenic factor VIII assay variability in post-infusion and spiked samples containing full-length recombinant FVIII or recombinant factor VIII Fc fusion protein (rFVIII:Fc). Int J Lab Hematol 2019;41(02):176–183

44 Owaidah TM, Alzahrani HA, Al-Nunais AO, Aguilos AM, Saleh M. Assessing the performance of extended half-life coagulation factor VIII, FC fusion protein by using chromogenic and one-stage assays in Saudi hemophilia A patients. Adv Hematol 2020;2020:8768074

45 Coyle TE, Reding MT, LIn JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 2014;12(04):488–496
mimicking the function of factor VIII cofactor activity. PLoS One 2013;8(02):e57479
82 Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012;18(10):1570–1574
83 Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood 2017;130(23):2463–2468
84 Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost 2019;119(07):1084–1093
85 Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb Haemost 2019;119(09):1384–1393
86 Amir J, Seghatchian J. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophilia patients. Transfus Apheresis Sci 2018;57(03):363–369
87 Santoro C, Quintavalle G, Castaman G, et al. Inhibitors in hemophilia B. Semin Thromb Hemost 2018;44(06):578–589
88 Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000;26(02):179–188
89 Holstein K, Albisetti M, Biddingmaier C, et al. Ständige Kommission Hämosthile (Haemophilia board) of the German, Swiss Austrian Society for Thrombosis Haemostasis Research (GTH) Practical guidance of the GTH Haemophilia Board on the use of emicizumab in patients with hemophilia A. Haemostaseologie 2020;40(05):561–571
90 Warrier I, Ewenstein BM, Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997;19(01):23–27
91 Abdi A, Bordbar MR, Hassan S, et al. Prevalence and incidence of non-neutralizing antibodies in congenital hemophilia A - a neutralizing review and meta-analysis. Front Immunol 2020;11:563
92 Miller CH, Boylan B, Payne AB, Driggers J, Bean CJ. Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab. Int J Lab Hematol 2021;43(02):e84–e86
93 Konkle BA, Stayshyin O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 2015;126(09):1078–1085
94 Mullins ES, Stayshyin O, Alvarez-Román MT, et al. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Haemophilia 2017;23(02):238–246
95 Meunier S, Alamelu J, Ehrenforth S, et al. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Thromb Haemost 2017;117(09):1705–1713
96 Santagostino E, Kenet G, Fischer K, Biss T, Ahuja S, Steele M. PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A. Haemophilia 2020;26(03):e55–e65
97 Lieuw K. Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? J Blood Med 2017;8:67–73
98 Schiavoni M, Napolitano M, Giuffrida G, et al. Status of recombinant factor VIII concentrate treatment for hemophilia A in Italy: characteristics and clinical benefits. Front Med (Lausanne) 2019;6:261
99 Fylling KA, Tange JL, Chen D, Pruthi RK. Heat inactivation of extended half-life factor VIII concentrates. Haemophilia 2019;25(02):e130–e131
100 Payne AB, Ellingsen D, Driggers J, Bean CJ, Miller CH. Evaluation of pre-analytic heat treatment protocol used in the CDC Nijmegen-Bethesda assay for heat inactivation of extended half-life haemophilia treatment products. Haemophilia 2020;26(01):e28–e30
101 Türkantoz H, Königs C, Knöbl P, et al. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: data from the GTH-AH 01/2010 study. J Thromb Haemost 2020;18(01):36–43
102 Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet 2021;397(10274):630–640
103 Croteau SE, Wang M, Wheeler AP. 2021 clinical trials update: innovations in hemophilia therapy. Am J Hematol 2021;96(01):128–144
104 Miesbach W, Eladly F. Current and future options of haemophilia A treatments. Expert Opin Biol Ther 2021;21(11):1395–1402
105 Trinchero A, Sholzberg M, Matino D. The evolution of hemophilia care: clinical and laboratory advances, opportunities, and challenges. Hamostaseologie 2020;40(03):311–321
106 Tripodi A, Chantarangkul V, Novembrino C, Peyvandi F. Advances in the treatment of hemophilia: implications for laboratory testing. Clin Chem 2019;65(02):254–262
107 Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med 2017;377(26):2519–2530
108 Robinson MM, George LA, Carr ME, et al. Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua. J Thromb Haemost 2021;19(05):1212–1218